{"title":"印度药用植物天然化合物联合抗雌激素阳性乳腺癌的虚拟筛选","authors":"Shaleen Jain, Asmita Das","doi":"10.31149/ijie.v3i10.750","DOIUrl":null,"url":null,"abstract":"Facing worldwide challenges associated with multifactorial etiology of breast cancer, designing of combinatorial therapies using natural compounds is currently the emergent way of treating several cancers including breast cancer in a synergistic way, which may mitigate several problems associated with multiple receptor targeting. In this research, Estrogen receptor positive breast cancer was taken as prototype and several key receptors associated with this particular disease were targeted by virtual screening of natural compounds found in Indian originated medicinal plants using Computer aided Drug Designing (CADD) strategies. We found the combination of Carpusin, Paulownin Cornigerine, Nororientaline, Oryzalexin B, Romucosine H and Colchicine as effective against six potential receptors i.e. FGFR2, ESR1, PIK3CA, PIK3CB, PIK3CD and AR in Estrogen receptor positive breast cancer with their binding energies in the range of ∆G ≤ -8.0 Kcal/mol as well as significant number of common amino acid binding residues as compared with binding sites of receptors. Thus this research holds significant implications for the designing of combinatorial therapeutic agents against breast cancer which can be further tested in-vitro and in-vivo to prove their synergistic efficiency.","PeriodicalId":350136,"journal":{"name":"International Journal on Integrated Education","volume":"238 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2020-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"3","resultStr":"{\"title\":\"Virtual screening of natural compounds as combinatorial agents from indian medicinal plants against estrogen positive breast cancer\",\"authors\":\"Shaleen Jain, Asmita Das\",\"doi\":\"10.31149/ijie.v3i10.750\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Facing worldwide challenges associated with multifactorial etiology of breast cancer, designing of combinatorial therapies using natural compounds is currently the emergent way of treating several cancers including breast cancer in a synergistic way, which may mitigate several problems associated with multiple receptor targeting. In this research, Estrogen receptor positive breast cancer was taken as prototype and several key receptors associated with this particular disease were targeted by virtual screening of natural compounds found in Indian originated medicinal plants using Computer aided Drug Designing (CADD) strategies. We found the combination of Carpusin, Paulownin Cornigerine, Nororientaline, Oryzalexin B, Romucosine H and Colchicine as effective against six potential receptors i.e. FGFR2, ESR1, PIK3CA, PIK3CB, PIK3CD and AR in Estrogen receptor positive breast cancer with their binding energies in the range of ∆G ≤ -8.0 Kcal/mol as well as significant number of common amino acid binding residues as compared with binding sites of receptors. Thus this research holds significant implications for the designing of combinatorial therapeutic agents against breast cancer which can be further tested in-vitro and in-vivo to prove their synergistic efficiency.\",\"PeriodicalId\":350136,\"journal\":{\"name\":\"International Journal on Integrated Education\",\"volume\":\"238 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2020-10-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"3\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal on Integrated Education\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.31149/ijie.v3i10.750\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal on Integrated Education","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.31149/ijie.v3i10.750","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 3
摘要
面对全球范围内与乳腺癌多因子病因学相关的挑战,利用天然化合物设计联合疗法是目前以协同方式治疗包括乳腺癌在内的几种癌症的新兴方法,这可能会缓解与多受体靶向相关的一些问题。本研究以雌激素受体阳性乳腺癌为原型,利用计算机辅助药物设计(Computer aided Drug design, CADD)策略对印度原产药用植物中发现的天然化合物进行虚拟筛选,筛选出与该疾病相关的几种关键受体。我们发现Carpusin、Paulownin山茱萸碱、Nororientaline、Oryzalexin B、Romucosine H和秋水仙碱联合使用对雌激素受体阳性乳腺癌中FGFR2、ESR1、PIK3CA、PIK3CB、PIK3CD和AR 6种潜在受体有效,其结合能在∆G≤-8.0 Kcal/mol范围内,与受体结合位点相比,常见氨基酸结合残基数量显著增加。因此,本研究对乳腺癌联合治疗药物的设计具有重要意义,可以进一步在体外和体内测试以证明其协同效果。
Virtual screening of natural compounds as combinatorial agents from indian medicinal plants against estrogen positive breast cancer
Facing worldwide challenges associated with multifactorial etiology of breast cancer, designing of combinatorial therapies using natural compounds is currently the emergent way of treating several cancers including breast cancer in a synergistic way, which may mitigate several problems associated with multiple receptor targeting. In this research, Estrogen receptor positive breast cancer was taken as prototype and several key receptors associated with this particular disease were targeted by virtual screening of natural compounds found in Indian originated medicinal plants using Computer aided Drug Designing (CADD) strategies. We found the combination of Carpusin, Paulownin Cornigerine, Nororientaline, Oryzalexin B, Romucosine H and Colchicine as effective against six potential receptors i.e. FGFR2, ESR1, PIK3CA, PIK3CB, PIK3CD and AR in Estrogen receptor positive breast cancer with their binding energies in the range of ∆G ≤ -8.0 Kcal/mol as well as significant number of common amino acid binding residues as compared with binding sites of receptors. Thus this research holds significant implications for the designing of combinatorial therapeutic agents against breast cancer which can be further tested in-vitro and in-vivo to prove their synergistic efficiency.